Torsades de Pointes associated with fluoroquinolones

Pharmacotherapy

Volumn 22, Issue 5, 2002, Pages 663-672

  Owens, Robert C ^a,b   Ambrose, Paul G ^c,d  

^a MAINE MEDICAL CENTER   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c Albany Medical College   (United States)

^d UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

CARDIOTOXICITY; CLINICAL TRIAL; DRUG APPROVAL; DRUG FORMULATION; DRUG INDUSTRY; DRUG INFUSION; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HEART VENTRICLE ARRHYTHMIA; HUMAN; NONHUMAN; PRESCRIPTION; QT INTERVAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; TORSADE DES POINTES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-INFECTIVE AGENTS; ELECTROCARDIOGRAPHY; FLUOROQUINOLONES; HUMANS; TORSADES DE POINTES;

EID: 0036235148     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.8.663.33201     Document Type: Review

References (30)

1. The safety profile of the fluoroquinolones
2. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes
3. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin
4. Antibiotic cardiotoxicity
5. Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors
6. How the US Food and Drug Administration defines and detects adverse drug events
7. Postmarketing surveillance and adverse drug reactions: Current perspectives and future needs
8. Adverse drug reactions: Physicians' opinions versus a causality assessment method
9. Temporal patterns of NSAID spontaneous adverse event reports: The Weber effect revisited
10. Adverse drug events and the Freedom of Information Act: An apple in Eden
11. Macrolide- and fluoroquinolone-associated torsade de pointes: Review of the FDA adverse event reporting system
12. Cisapride-induced torsades de pointes
13. Multicenter trial of sotalol compared with procainamide in the suppression of inducible ventricular tachycardia: A double-blind, randomized parallel evaluation
14. Voluntary systems of adverse reaction reporting - Part I
15. Voluntary systems of adverse reaction reporting - Part II
16. Voluntary systems of adverse reaction reporting - Part III
17. Seasonal variation in fluoroquinolone prescribing
18. Organising evidence on QT prolongation and occurrence of torsades de pointes with non-antiarrhythmic drugs: A call for consensus
19. The pre-clinical assessment of QT interval prolongation: A comparison of in vitro and in vivo models
20. The QT interval and torsade de pointes
21. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K-channel HERG
22. Effects of fluoroquinolones on HERG currents
23. Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics
24. Effect of three fluoroquinolones on QTc in healthy volunteers
25. Safety of gatifloxacin in patients with cardiovascular disease
26. Gatifloxacin-induced QTc prolongation and ventricular tachycardia
27. Moxifloxacin does increase the corrected QT interval
28. Reassuring safety profile of moxifloxacin
29. Quinolone-induced QT interval prolongation: A not-so-unexpected class effect